Study of the Atopic March: Development of Atopic Comorbidities

Schneider, L.; Hanifin, J.; Boguniewicz, M.; Eichenfield, L. F.; Spergel, J. M.; Dakovic, R.; Paller, A. S.

Pediatr Dermatol. 2016 Jun 9; 33(4):388-98

Abstract

BACKGROUND: Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety. METHODS: This was a 3-year double-blind study in which patients were randomized to pimecrolimus or vehicle and then open-label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease-free days, Eczema Area and Severity Index, and body surface area affected. RESULTS: Infants ages 3 to 18 months with recent-onset AD (

Read More on PubMed